Pentadeca Arginate
Also known as: PDA, BPC-157 arginate salt
A modified form of BPC-157 stabilized as an arginate salt, designed to be more stable at room temperature and suitable for oral administration research.
Overview
Pentadeca Arginate (PDA) is a stable salt form of the BPC-157 pentadecapeptide in which the peptide is associated with arginine. This modification is intended to confer greater stability in aqueous environments and at room temperature compared to the acetate form of BPC-157, potentially making it more practical for oral research applications.
The fundamental peptide sequence and proposed mechanisms of action are shared with BPC-157, but research is ongoing into whether the arginate modification alters bioavailability, potency, or the tissue distribution profile. PDA has generated interest as a potentially oral-stable alternative for gastrointestinal and systemic applications where BPC-157 has shown promise.
Mechanism of Action
Shares BPC-157's mechanism of upregulating growth factor receptors (VEGFR2, EGFR), promoting angiogenesis via the FAK-paxillin pathway, modulating the NO system, and activating cytoprotective gene programs. The arginate salt modification may improve GI stability and absorption.
Research Areas
- ●Oral bioavailability of BPC-157 variants
- ●GI mucosal protection
- ●Tendon and tissue repair
- ●Stability and formulation research
- ●Comparison with BPC-157 acetate
Storage & Handling
More stable at room temperature than BPC-157 acetate; lyophilized: -20°C recommended.
Soluble in sterile water
For Research Use Only. This information is provided for educational and research purposes. Pentadeca Arginate is not approved for human consumption, veterinary use, or clinical application. All research must be conducted in accordance with applicable laws and institutional guidelines.